drugset
Drugs / Gatipotuzumab
last change Dec 2021 re-read 9 days ago

Gatipotuzumab

also known as PankoMab-GEX

Monoclonal antibody targets MUC1

Developed for
cancer · fallopian tube cancer · malignant epithelial tumor of ovary · primary peritoneal carcinoma
Investigated by
Glycotope GmbH

Trials 2

today NCT03360734 · Ph 1 NCT01899599 · Ph 2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03360734 Nov 2017 → May 2020 cancer Glycotope GmbH Completed No outcome recorded
Phase 21 trial · 1 missed
Phase 2 NCT01899599 Sep 2013 → Apr 2017 fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma Glycotope GmbH Completed Missed primary

Press releases naming this drug 1 release

DateIssuerRelease
2018-07-30 Daiichi Sankyo Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate daiichisankyo.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Gatipotuzumab “Gatipotuzumab is a humanized monoclonal antibody recognizing the carbohydrate-induced epitope of the tumor-associated mucin-1 (TA-MUC1).” PMID 34920291 ↗ Dec 2021
1

NCT03360734 ↗
Known as PankoMab-GEX “Gatipotuzumab (PankoMab-GEX®) is a novel glyco-engineered humanized monoclonal antibody” NCT03360734 ↗
Modality Monoclonal antibody “Gatipotuzumab (PankoMab-GEX®) is a novel glyco-engineered humanized monoclonal antibody” NCT03360734 ↗
Route Intravenous “receive intravenous gatipotuzumab” PMID 34920291 ↗ Dec 2021
Target MUC1 “Gatipotuzumab targets and binds TA-MUC1 epitopes on the surface of tumor cells” NCT03360734 ↗